Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Masuda

Showing results (191-200 of 298) with videos related to

Pageof 30
Sort By:
Thoracic Cancer|January 25, 2022
First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutationsNoriaki Ito, Takeshi Masuda, Ikuko Ooka, et al.
Scientific Reports|February 22, 2023
Preserved ratio impaired spirometry with or without restrictive spirometric abnormalityShinichiro Miura, Hiroshi Iwamoto, Keitaro Omori, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLCKunihiko Funaishi, Kakuhiro Yamaguchi, Hiroki Tanahashi, et al.
Respiratory Medicine Case Reports|October 14, 2024
Primary pulmonary extranodal NK/T-cell lymphoma diagnosed by thoracoscopic lung biopsy: A case reportMichihiko Tanaka, Yasushi Horimasu, Kazuma Kawamoto, et al.
Molecular Therapy. Nucleic Acids|December 1, 2025
Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppressionArisa Hamada, Kiyofumi Shimoji, Taku Nakashima, et al.
BMJ Open Respiratory Research|February 20, 2024
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosisShinichiro Miura, Hiroshi Iwamoto, Masashi Namba, et al.
The European Respiratory Journal|September 30, 2021
Accelerated decline in lung function in adults with a history of remitted childhood asthmaShinichiro Miura, Hiroshi Iwamoto, Keitaro Omori, et al.
Respiration; International Review of Thoracic Diseases|August 16, 2019
C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity PneumonitisMasako Watanabe, Yasushi Horimasu, Hiroshi Iwamoto, et al.
Respiratory Research|November 11, 2024
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort studyErika Kitadai, Kakuhiro Yamaguchi, Shinichiro Ohshimo, et al.
Respiratory Medicine|May 27, 2019
Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumoniaSachiko Shioya, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
Pageof 30

Showing results (191-200 of 298) with videos related to

Sort By:
Pageof 30
Thoracic Cancer|January 25, 2022
First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutationsNoriaki Ito, Takeshi Masuda, Ikuko Ooka, et al.
Scientific Reports|February 22, 2023
Preserved ratio impaired spirometry with or without restrictive spirometric abnormalityShinichiro Miura, Hiroshi Iwamoto, Keitaro Omori, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLCKunihiko Funaishi, Kakuhiro Yamaguchi, Hiroki Tanahashi, et al.
Respiratory Medicine Case Reports|October 14, 2024
Primary pulmonary extranodal NK/T-cell lymphoma diagnosed by thoracoscopic lung biopsy: A case reportMichihiko Tanaka, Yasushi Horimasu, Kazuma Kawamoto, et al.
Molecular Therapy. Nucleic Acids|December 1, 2025
Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppressionArisa Hamada, Kiyofumi Shimoji, Taku Nakashima, et al.
BMJ Open Respiratory Research|February 20, 2024
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosisShinichiro Miura, Hiroshi Iwamoto, Masashi Namba, et al.
The European Respiratory Journal|September 30, 2021
Accelerated decline in lung function in adults with a history of remitted childhood asthmaShinichiro Miura, Hiroshi Iwamoto, Keitaro Omori, et al.
Respiration; International Review of Thoracic Diseases|August 16, 2019
C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity PneumonitisMasako Watanabe, Yasushi Horimasu, Hiroshi Iwamoto, et al.
Respiratory Research|November 11, 2024
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort studyErika Kitadai, Kakuhiro Yamaguchi, Shinichiro Ohshimo, et al.
Respiratory Medicine|May 27, 2019
Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumoniaSachiko Shioya, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
Pageof 30